title: [Reactivation of hepatitis B after treatment with CHOP and rituximab].
authors.forename: F J
authors.initials: FJ
authors.lastname: Fernández Fernández
authors.forename: J
authors.initials: J
authors.lastname: de la Fuente Aguado
authors.forename: R
authors.initials: R
authors.lastname: Puerta Louro
authors.forename: A
authors.initials: A
authors.lastname: Fernández Villaverde
authors.forename: C
authors.initials: C
authors.lastname: Soto Ríos
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D019694:Hepatitis B, Chronic / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects; D012008:Recurrence; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone